STUDI PENGGUNAAN ANTIKOAGULAN WARFARIN PADA PASIEN DENGAN FIBRILASI ATRIUM (Penelitian dilakukan di Poli Jantung Instalasi Rawat Jalan Rumah Sakit Universitas Airlangga)

Atrial Fibrillation is one of the risk factors of stroke. For now, warfarin is the most common solution for AF therapy but warfarin has many problems such as the low outcome warfarin therapy, 80% interact with other drugs, certain foods, having a narrow therapeutic index, 99% bonded to plasma proteins, has two active isomers. Thus, it is important to do research about “Drug Utilization Of Warfarin”. The purpose of this study was to describe the use of warfarin that occurs in patients with AF including dose usages, drug interactions, side effects and outcome therapy. Retrospectively by collecting data from the patient medical record all the AF patients that receive warfarin therapy in outpatient cardiology unit in Universitas Airlangga Hospital from 2015 to 2018. The data was analyze descriptively. The study found as much as 50 patients with AF. The most widely used initial dose of warfarin was 2 mg to (70%) and the most widely used maintenance dose was 2 mg (48.95%). Proportion of INR in target range was 33,82%. The potential side effects of warfarin usage such as experienced bleeding that occurs in 6% patients and there was suspected a potential of drug interactions due to the use of warfarin in conjunction with Amiodarone (0,28 %). Warfarin also interacts with other drugs such as Simvastatin (36.22%). Outcome therapy of warfarin was not adequate